<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347097</url>
  </required_header>
  <id_info>
    <org_study_id>KY2017-241</org_study_id>
    <nct_id>NCT03347097</nct_id>
  </id_info>
  <brief_title>PD1-PIK Cell Therapy for Patients With Glioblastoma Multiforme</brief_title>
  <official_title>The Safety and Efficacy Study of PD1-PIK Cell Therapy for Patients With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, the investigators constructed a transgenic modified T cells,namely pluripotent
      immune killer (PIK) cells, the cells can stablely express a high-level full-length PD1
      antibody , transduce signals to activate T cells, which results in tumor killing. This pilot
      study is to determine the safety and efficacy of autologous T cells in patients with
      glioblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events related to pd-1-pik cell infusion</measure>
    <time_frame>1 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Responses Rate</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>PD-1-PIK T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days after the end of concurrent chemoradiotherapy，the 300ml PD-1-PIK cells ( PD-1-PIK saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pd-1-pik</intervention_name>
    <arm_group_label>PD-1-PIK T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed brain glioblastoma multiforme.

          2. Patients with maximum safe resection of the tumor (≥95%) confirmed with contrast MR
             within 72 hours after surgery.

          3. Age from 18 to 70 years.

          4. Karnofsky performance score ≥ 60.

          5. Adequate organ function within 14 days of study registration including the following:
             Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count, (ANC) ≥
             1.0×10^9/L, platelets ≥100×10^9/L; hemoglobin ≥ 9 g/dL. Hepatic: bilirubin ≤1.3 mg/dL
             or 0-22 mmol/L, aspartate transaminase (AST) and alanine transaminase (ALT) &lt; 3×upper
             limit of normal (ULN). Renal: Normal serum Creatinine for age (below) or creatinine
             clearance &gt;60 ml/min/1.73 m2. Electrocardiogram: normal.

          6. Written informed consent must be obtained from all patients.

        Exclusion Criteria:

          1. Pregnant or breast-feeding patients. Pregnancy testing will be performed on all
             menstruating females within 14 days of study enrollment.

             Patients with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             or psychiatric illness/social situations that would limit compliance with study
             requirements.

          2. Patients with history of immune system abnormalities such as hyperimmunity (e.g.,
             autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrow
             failures, AIDS, ongoing pregnancy, transplant immuno-suppression), or medication of
             cortisol.

          3. Patients with any conditions that could potentially alter immune function (e.g., AIDS,
             multiple sclerosis, diabetes, renal failure).

        Patients currently received any other investigational agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>liang zhou, dr</last_name>
    <email>lfzhouc@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jun qian, dr</last_name>
    <email>qianqj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Yao, MD, PhD</last_name>
      <email>yu_yao03@126.com</email>
    </contact>
    <contact_backup>
      <last_name>chao tang, MD</last_name>
      <email>tangchao12345678@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 18, 2017</last_update_submitted>
  <last_update_submitted_qc>November 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojie Ding</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>pd-1</keyword>
  <keyword>pd-L1</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

